Drug Interactions between allopurinol and Veozah
This report displays the potential drug interactions for the following 2 drugs:
- allopurinol
- Veozah (fezolinetant)
Interactions between your drugs
allopurinol fezolinetant
Applies to: allopurinol and Veozah (fezolinetant)
CONTRAINDICATED: Coadministration with inhibitors of CYP450 1A2 may significantly increase the plasma concentrations of fezolinetant, which is primarily metabolized by the isoenzyme. In clinical drug interaction studies, coadministration of the potent CYP450 1A2 inhibitor fluvoxamine increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 80% and 840%, respectively. Likewise, the moderate CYP450 1A2 inhibitor, mexiletine, is predicted through physiologically based pharmacokinetic (PBPK) modeling to increase the Cmax and AUC of fezolinetant by 40% and 360%, respectively. The weak CYP450 1A2 inhibitor cimetidine is also predicted via PBPK to increase the Cmax and AUC of fezolinetant by 30% and 100%, respectively.
MANAGEMENT: Concomitant use of fezolinetant with CYP450 1A2 inhibitors is considered contraindicated.
References (5)
- (2024) "Product Information. Veoza (fezolinetant)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. Veozah (fezolinetant)." Astellas Pharma Canada Inc
- (2025) "Product Information. Veoza (fezolinetant)." Astellas Pharma Ltd
- (2024) "Product Information. Veozah (fezolinetant)." Astellas Pharma US, Inc
- Pollock BG, Wylie M, Stack JA, et al. (1999) "Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women." J Clin Pharmacol, 39, p. 936-40
Drug and food interactions
fezolinetant food
Applies to: Veozah (fezolinetant)
CONTRAINDICATED: Coadministration with inhibitors of CYP450 1A2 such as caffeine may significantly increase the plasma concentrations of fezolinetant, which is primarily metabolized by the isoenzyme. The interaction has not been studied with caffeine but has been reported for other CYP450 1A2 inhibitors. Consumption of caffeine-containing food or beverages (e.g., chocolate, coffee, cola drinks, energy drinks, tea) could result in an interaction with fezolinetant. In clinical drug interaction studies, coadministration of the potent CYP450 1A2 inhibitor fluvoxamine increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 80% and 840%, respectively. Likewise, the moderate CYP450 1A2 inhibitor, mexiletine, is predicted through physiologically based pharmacokinetic (PBPK) modeling to increase the Cmax and AUC of fezolinetant by 40% and 360%, respectively. The weak CYP450 1A2 inhibitor cimetidine is also predicted via PBPK to increase the Cmax and AUC of fezolinetant by 30% and 100%, respectively.
MANAGEMENT: Concomitant use of fezolinetant with CYP450 1A2 inhibitors such as caffeine, including caffeine-containing food or beverages, is considered contraindicated.
References (4)
- (2024) "Product Information. Veoza (fezolinetant)." Astellas Pharma Australia Pty Ltd
- (2024) "Product Information. Veozah (fezolinetant)." Astellas Pharma Canada Inc
- (2025) "Product Information. Veoza (fezolinetant)." Astellas Pharma Ltd
- (2024) "Product Information. Veozah (fezolinetant)." Astellas Pharma US, Inc
allopurinol food
Applies to: allopurinol
ADJUST DOSING INTERVAL: The tolerability of allopurinol may be improved by giving it after a meal. Additionally, when the dose is greater than 300 mg, dividing the total daily dose into smaller doses administered more often may be appropriate to help minimize gastrointestinal irritation.
MONITOR: Concomitant use of allopurinol with central nervous system (CNS) depressants, including alcohol, may potentiate adverse effects such as somnolence and sedation.
MANAGEMENT: To improve tolerability, some manufacturers suggest administering allopurinol after a meal. Additionally, if the daily dose is greater than 300 mg, administering allopurinol in divided doses may help reduce gastrointestinal intolerance. Patients should also be counseled to avoid or limit consumption of alcohol and to avoid activities requiring mental alertness such as driving or operating hazardous machinery until they know how the medication affects them.
References (4)
- (2024) "Product Information. Allopurinol (Sandoz) (allopurinol)." Sandoz Pty Ltd
- (2021) "Product Information. Zyloric (allopurinol)." Aspen Pharma Trading Ltd
- (2021) "Product Information. Zyloprim (allopurinol)." AA Pharma Inc, 248178
- (2024) "Product Information. Allopurinol (allopurinol)." Actavis U.S. (Purepac Pharmaceutical Company)
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.